Anionic dye or brightener bearing an ammonium or phosphonium counterion, dye composition comprising them and process for dyeing keratin fibres using these dyes
US-2015113742-A1 · Apr 30, 2015 · US
Compositions and methods for targeting a viral infection
US12064425B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-12064425-B2 |
| Application number | US-201917262540-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 26, 2019 |
| Priority date | Jul 27, 2018 |
| Publication date | Aug 20, 2024 |
| Grant date | Aug 20, 2024 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein are compounds that inhibits the membrane proximal external region (MPER) of a viral envelope (Env), as well as and compositions thereof. Further provided herein are methods for treating or preventing a viral infection comprises administering to a subject in need thereof an agent or compound that inhibits the MPER of a viral Env. In certain embodiments, the viral infection is an HIV infection.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a viral infection, the method comprising: administering to a subject in need thereof an agent that inhibits the membrane proximal external region (MPER) of a viral envelope (Env), wherein the viral infection is a human immunodeficiency virus-1 (HIV-1) infection or a human immunodeficiency virus-2 (HIV-2) infection, wherein the agent that inhibits MPER is S2C3. 2. The method of claim 1 , wherein the viral envelope is the HIV-1 or HIV-2 Env. 3. The method of claim 1 , wherein inhibiting MPER results in the inhibition of Env fusion to the target cell. 4. The method of claim 1 , further comprising, prior to administering, the step of diagnosing a subject as having an HIV-1 or HIV-2 infection, or receiving the results of an assay that diagnoses a subject as having an HIV-1 or HIV-2 infection. 5. The method of claim 1 , wherein the HIV-1 or HIV-2 infection is resistant to at least one HIV treatment. 6. The method of claim 5 , wherein the HIV- 1 infection is resistant to an inhibitor of HIV- 1 fusion to a target cell. 7. The method of claim 6 , wherein the inhibitor of HIV-1 fusion is Maravirox, Enfuvirtide, Sifuvirtide, or Albuvirtide. 8. The method of claim 6 , wherein the target cell is a leukocyte, a lymphocyte, a T cell, or a CD 4 +T cell.
Assignees
Inventors
Classifications
containing carbocyclic rings other than six-membered · CPC title
attached in position 9 · CPC title
with only hydrocarbon or substituted hydrocarbon radicals attached in position 2 · CPC title
having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom · CPC title
Unsubstituted amino or imino radicals · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US12064425B2 cover?
- Described herein are compounds that inhibits the membrane proximal external region (MPER) of a viral envelope (Env), as well as and compositions thereof. Further provided herein are methods for treating or preventing a viral infection comprises administering to a subject in need thereof an agent or compound that inhibits the MPER of a viral Env. In certain embodiments, the viral infection is an…
- Who is the assignee on this patent?
- Childrens Medical Ct Corp
- What technology area does this patent fall under?
- Primary CPC classification A61K31/4709. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 20 2024 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).